Medicure Inc (MCUJF)

[Dennisb68]

Medicure to Present at Deutsche Bank's Annual Health Care Conference
Tuesday May 1, 9:00 am ET


WINNIPEG, MANITOBA--(MARKET WIRE)--May 1, 2007 -- Medicure Inc. (Toronto:MPH.TO - News)(AMEX:MCU - News), a cardiovascular focused biopharmaceutical company, today announced its President and CEO, Albert D. Friesen, PhD, will deliver a corporate presentation at Deutsche Bank's 32nd Annual Health Care Conference at 4 p.m. Eastern on Wednesday May 2, 2007 in the Chinese Room of The Mayflower Hotel in Washington, D.C. The presentation will be made available by webcast and can be accessed on the Investor Relations page of the Medicure website at www.medicure.com.
ADVERTISEMENT


About Medicure Inc.

Medicure is a biopharmaceutical company focused on the research, development and commercialization of novel compounds to treat cardiovascular disorders. The Company's solid position in this field is highlighted by the following:

- Two drugs, MC-1 & MC-4232, in late stage clinical development

- Four positive Phase II trials completed with MC-1

- FDA Fast Track designation for MC-1

- U.S. rights to AGGRASTAT® Injection (tirofiban hydrochloride)

- Dual action antithrombotic, MC-45308, with positive preclinical results

Medicure also has a medicinal chemistry based Drug Discovery program focused on discovery and advancement of novel small molecule anti-ischemics and antithrombotics towards human clinical studies.